These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. Peker A; Çiçek O; Soydal Ç; Küçük NÖ; Bilgiç S Diagn Interv Radiol; 2015; 21(1):54-9. PubMed ID: 25430526 [TBL] [Abstract][Full Text] [Related]
7. Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. Kennedy A; Coldwell D; Sangro B; Wasan H; Salem R Am J Clin Oncol; 2012 Aug; 35(4):393-8. PubMed ID: 21278561 [TBL] [Abstract][Full Text] [Related]
8. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Maire F; Lombard-Bohas C; O'Toole D; Vullierme MP; Rebours V; Couvelard A; Pelletier AL; Zappa M; Pilleul F; Hentic O; Hammel P; Ruszniewski P Neuroendocrinology; 2012; 96(4):294-300. PubMed ID: 22507901 [TBL] [Abstract][Full Text] [Related]
9. Intra-arterial hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II study. Fiorentini G; Rossi S; Bonechi F; Vaira M; De Simone M; Dentico P; Bernardeschi P; Cantore M; Guadagni S J Chemother; 2004 Jun; 16(3):293-7. PubMed ID: 15330328 [TBL] [Abstract][Full Text] [Related]
10. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice. Grozinsky-Glasberg S; Kaltsas G; Kaltsatou M; Lev-Cohain N; Klimov A; Vergadis V; Uri I; Bloom AI; Gross DJ Endocrine; 2018 Jun; 60(3):499-509. PubMed ID: 29383678 [TBL] [Abstract][Full Text] [Related]
11. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Saxena A; Chua TC; Bester L; Kokandi A; Morris DL Ann Surg; 2010 May; 251(5):910-6. PubMed ID: 20395859 [TBL] [Abstract][Full Text] [Related]
16. Radioembolization in the treatment of neuroendocrine tumors of the pancreas. John PK; Saif MW JOP; 2014 Jul; 15(4):332-4. PubMed ID: 25076336 [TBL] [Abstract][Full Text] [Related]
17. Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver. Kvols LK; Turaga KK; Strosberg J; Choi J J Natl Compr Canc Netw; 2009 Jul; 7(7):765-72. PubMed ID: 19635229 [TBL] [Abstract][Full Text] [Related]
18. Radioembolization Versus Chemoembolization for Neuroendocrine Metastases. Padia SA J Vasc Interv Radiol; 2021 Mar; 32(3):482-483. PubMed ID: 33376030 [No Abstract] [Full Text] [Related]
19. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. Ho AS; Picus J; Darcy MD; Tan B; Gould JE; Pilgram TK; Brown DB AJR Am J Roentgenol; 2007 May; 188(5):1201-7. PubMed ID: 17449759 [TBL] [Abstract][Full Text] [Related]
20. Role of Radioembolization in Metastatic Neuroendocrine Tumors. Lewandowski RJ; Toskich BB; Brown DB; El-Haddad G; Padia SA Cardiovasc Intervent Radiol; 2022 Nov; 45(11):1590-1598. PubMed ID: 35918431 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]